POGO

icon-facebook

Satellite Manual

4.2 Pentamidine Administration

4.2.1 Inhaled Pentamidine

Only individuals who have been trained on the safe handling and administration of pentamidine may perform this procedure.

Purpose
The Registered Nurse or respiratory therapist administers aerosolized pentamidine to the patient for the prevention of Pneumocystis jiroveci, formerly carinii, pneumonia (PCP or PJP).  PJP can be severe or fatal if not promptly treated.  It can affect the lungs as well as other parts of the body, including the skin and internal organs.

Overview
Pentamidine is an antiprotozoal agent commonly used as a second-line therapy to help prevent the growth of pneumocystis jiroveci a microorganism often found in the lungs of patients who are immunosuppressed.  When pentamidine is delivered as an aerosol it has limited absorption from the respiratory tract into the systemic circulation and therefore has fewer systemic side effects than when given intravenously.

Pentamidine is administered via the Respirgard II Nebulizer, which utilizes a series of one-way valves and a filter to minimize the release of aerosol droplets into the air. Aerosolized pentamidine may be potentially toxic necessitating this special nebulization system. The standard dose is 300 mg of lyophilized pentamidine isethionate dissolved in sterile water and aerosolized until the nebulizer runs dry. Inhaled pentamidine is given on a monthly basis.

Precautions
Adequate ventilation is required.  Some tertiary centres conduct the procedure in a HEPA-filtered exhaust containment booth.  This booth is serviced and certified every 12 months.  Other centres should use a negative pressure room.  If you did not have a negative pressure room use a portable HEPA filter.

Pediatric patients require a pre treatment nursing assessment. Ensure age and cooperation level of patient are congruent with the ability to receive inhaled pentamidine. Do not administer pentamidine to pregnant patients, unless clearly indicated.  Staff may experience irritation of the conjunctivae or respiratory system, or respiratory or skin allergies if overexposed to pentamidine.  Staff must administer pentamidine using all appropriate precautions to minimize exposure. Only centres with proper equipment and trained personnel should administer inhaled pentamidine. Refer to hospital policy.  The National Institute of Occupational Safety and Health (NIOSH) removed pentamidine from the hazardous drug list in 2014.

There is little information regarding long term effects of aerosolized pentamidine on health care workers. There is documentation stating aerosolized pentamidine to be embryotoxic in animals. (Tsai, Boiano and Sweeney 1410). The risks involved in administration can be reduced significantly if one adheres to standard safety precautions; however, pregnant women should reduce their exposure as there is insufficient data on additional risks during pregnancy. Please refer to your institutional policies and guidelines regarding safe handling.

Equipment and Materials

Oxygen flowmeter with nipple adapter

 

Negative Pressure room  or HEPA filter machine with private room

 

Respirgard II nebulizer system with mouthpiece and nose clips or appropriate size mask

 

Pentamidine (300 mg) prepared by pharmacy

If under 5 years of age please consult with the tertiary center on dosage 

 

Particulate N95 mask for staff staying in room with the patient

 

Stethoscope

 

Bronchodilator with nebulizer or aero-chamber

 

Personal protective equipment (PPE) as appropriate for hazardous agents

Pentamidine Aerosolization with the Respirgard II Nebulizer System

 

Procedure

Rationale

1.

Obtain a medical order for pentamidine   inhalation treatment and a bronchodilator.

Risk of bronchospasm or cough. Patients who exhibit signs of cough or bronchospasm may benefit from inhaled bronchodilator prior to pentamidine treatment.

2.

Explain procedure to patient including personal protective equipment.  Also explain the need to limit the number of disconnections and the procedure to use in case the patient starts coughing.  If using HEPA filter, place running filter machine in room 1 hour before starting treatment.

HEPA filter must be running in room pre treatment.  Private room, with door closed.

Pentamidine should be administered under close supervision.

3.

Obtain a careful respiratory history (eg. asthma, smoker).  Assess and record patient’s pulse, respiratory rate and breathing.

Bronchodilator should be readily available. 

4.

Wash hands.  Put on personal protective equipment.  Enter room. Door must remain closed.

Staff using an N95 mask must be fit tested. Staff administering pentamidine must wear personal protective equipment.

5.

Assemble the Respirgard II Nebulizer, connect extension tubing to oxygen flow meter or cylinder.  Add the pentamidine solution to the medication chamber on the nebulizer.

 

6.

Use a facemask or mouth piece and nose clips as per nursing assessment.  Ask the patient to put on nose clips (if using) and to place the mouthpiece in their mouth and encourage them to breathe normally.  Start flow meter. Use 5-8 LPM on flowmeter or 5-8 LPM on cylinder. Adjust flow to meet patients’ needs.

Watch for a good seal around the mouthpiece, air expansion and normal breathing.    

 

7.

Observe and assess respiratory status. Monitor for any signs of respiratory distress and administer bronchodilators as indicated. Turn off the flow and contact physician immediately if the patient develops wheezing or bronchospasm.

Common side effects include cough, bronchospasm, metallic taste, burning sensation in back of throat, and fatigue. Some patients may require additional bronchodilators.

8.

Instruct the patient to raise hand when requesting a break.  Stop the flow meter before the patient removes the mouthpiece from their mouth.  Do not restart flow meter until patient has mouthpiece back in their mouth.

Treatment will take approximately 15 minutes.

9.

At the end of the procedure, stop the flow meter before the patient removes the mouthpiece from their mouth. Instruct patient to rinse mouth and wash hands prior to leaving the room.  Keep the HEPA filter running with the door closed.  Discard the nebulizer, PPE and medication syringe in the cytototxic waste bin.

 

Staff should not enter the room without PPE until 60 minutes after the treatment is completed.  Housekeeping must wear gloves when cleaning but do not need to wear respiratory protection.  Use wet method when cleaning to avoid creating dust. 

Housekeeping may clean the room 1.5 hours after the last procedure.  Leave HEPA filter running with door closed  for 60 minutes post treatment.

10.

Assess pulse and respiratory rate.

Observe for respiratory distress.

11.

Document treatment and observations in the patient’s medical records chart.

 

First Aid Measures
For eye or mucous membrane splashes of contact with pentamidine, immediately flush contaminated area with running water for at least 15 minutes.  Obtain medical attention.

For skin contact with pentamidine, remove highly contaminated clothing and flush contaminated skin with running water for 15 minutes.  Obtain medical attention.

For accidental inhalation of pentamidine, leave the area and obtain medical attention.

Document all exposures as per hospital policy.

References

  1. Beach JR, Campbell M, Andrew DJ. Exposure to health care worker to pentamidine isethionate. Occupational. Medicine 1999; 49: 243-245.
  2. British Occupational Hygiene Society. Pentamidine. Control of Substances Hazardous to Health (COSHH) Guidance 2006 Jun; Guidance note 0306.
  3. Critical Care Medicine Department, National Institutes of Health, Warren G. Magnuson Clinical Centre. Pentamidine aerosolization with the Respirgard II Nebulizer System.
  4. ISSA International Section on the Prevention of Occupational Risks in Health Services, Occupational risk prevention in aerosol therapy (pentamidine).
  5. NIOSH [2014]. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2014. By Connor TH, MacKenzie BA, DeBord DG, Trout DB, O’Callaghan JP.. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupa­tional Safety and Health, DHHS (NIOSH) Publication No. 2014-138 (Supersedes 2012-150).retrieved from : http://www.cdc.gov/niosh/docket/archive/pdfs/NIOSH-233/0233-2014-138ListofAntineoplastic2014.pdf
  6. Occupational Safety & Health Administration (OSHA) Archive, Hazardous medications Retrieved from http://www.osha.gov/archive/oshinfo/priorities/medication.html
  7. Sick Kids, Toronto. Policies and Drug Information for Nurses, Aerosol administration of Pentamidine. 2005 Feb.
  8. Tsai, R., Boiano, J., Steege, A., & Sweeney, M. (2015). Precautionary Practices of Respiratory Therapists and Other Health-Care Practitioners Who Administer Aerosolized Medications. Respiratory Care, 60(10), 1409-1417. doi:10.4187/respcare.03817

Primary author Ms. Patti Bambury, Grand River Hospital, Kitchener with input from Ms. Ursula DeBono, Windsor Regional Hospital, Windsor, Ms. Denise Reniers, Children’s Hospital, London Health Sciences Centre and Mr. John Wiernikowski, McMaster Children’s Hospital, Hamilton Health Sciences Centre, Hamilton. Reviewed by POGO Satellite Manual Review Nursing Group, 2016 and the POGO Satellite Manual Review Pharmacy Working Group, 2016.

4.2.2 Intravenous Pentamidine
Back to Top

In this Section

  • 1.1 History & Overview
  • 1.2 Acknowledgements
  • 1.3 Committees and Working Groups
  • 1.4 Satellite Manual Disclaimer
  • 2.1 Principles of Satellite Care
  • 2.2 Eligible Patients
    • 2.2.1 Children Eligible for Chemotherapy Administration in a Satellite Centre
    • 2.2.2 Children Not Eligible for Chemotherapy Administration in a Satellite Centre
    • 2.2.3 Children Eligible for the Management of Complications on a Satellite Centre
    • 2.2.4 Eligibility of Children Requiring Supportive Care
  • 2.3 Scope of Satellite Practice
    • 2.3.1 Implementation of Psychosocial Treatment Plan (Process for Communication)
    • 2.3.2 Limitations on Satellite Practice
  • 2.4 Advanced Satellite Practice
  • 3.1 Safe Handling, Administration and Disposal of Chemotherapy Agents
  • 3.2 Accidental Exposure/Spills
  • 3.3 Extravasation Management
    • 3.3.1 Sample Extravasation Documenting Tool
  • 3.4 Injecting SC Medication Via an Insuflon
  • 3.5 Chemotherapy Administration Reference List
  • 3.6 Central Venous Catheter Care
  • 3.7 Chemotherapy Quick Reference
    • 3.7.1 Rapid Hydration Document
    • 3.7.2 Provider Guide: Prevention and Management or Irinotecan induced Diarrhea
    • 3.7.3 Parent Handout: Prevention and Management of Irinotean induced diarrhea
    • 3.7.4 Capizzi Methotrexate
    • 3.7.5 Erwinia L-Asparaginase
  • 4.1 Management of Fever and Neutropenia
    • 4.1.1 Routine Order Sample Sheet
    • 4.1.2 Fever Cards (Sample)
    • 4.1.3 Criteria for low-risk designation. Risk categorization refers to risk of bacteremia and serious complications, including mortality.
  • 4.2 Pentamidine Administration
    • 4.2.1 Inhaled Pentamidine
    • 4.2.2 Intravenous Pentamidine
  • 4.3 Antiemetics
  • 4.4 Treatment of Varicella-Zoster Infections
  • 4.5 TPN Document
  • 4.6 Immunization of Children with Cancer
  • 4.7 Transfusion
  • 4.8 When to consult the Tertiary Centre
  • 5.1 Palliative Care Overview
  • 5.2 Communication
  • 5.3 Settings of Care
  • 5.4 Symptom Management
  • 5.5 End of Life
  • 5.6 When a Child Dies in the Satellite Centre
    • 5.6.1 Reconciling your grief
    • 5.6.2 Funeral arrangement checklist
    • 5.6.3 Helping Children who grieve
    • 5.6.4 Coping with the Holidays
    • 5.6.5 The grieve experience
  • 6.1 Goals and Objectives
  • 6.2 Participant Site Selection
    • 6.2.1 Tertiary Site Selection
    • 6.2.2 Community Site Selection
  • 6.3 POGO’s Roles
    • 6.3.1 PHIPA, Privacy and Research
  • 6.4 Funding
    • 6.4.1 Funding Support for Tertiary Activity
    • 6.4.2 Financial Support for Pediatric Oncology Community Activity
  • 6.5 Infrastructure and Formal Requirements
    • 6.5.1 Tertiary Partners’ Role in Provincial Pediatric Oncology Satellite Program
    • 6.5.2 Satellite Partners’ Role in Provincial Pediatric Oncology Satellite Program
  • 7.1 Preamble
  • 7.2 Investigator responsibilities
  • 7.3 Training Requirements
    • 7.3.1 General Training for Conduct of Research
    • 7.3.2 Protocol Specific Training
  • 7.4 Research Activites that may be completed in satellite centres under supervision of DSI
  • 7.5 Research Activities to be completed in Tertiary Centres Only
  • 7.6 Recognition and Reporting of Adverse Events (AEs)
  • 7.7 Data Transfer
  • 7.8 Pharmacy Drug Accountibility
  • 7.9 Site Inspections and Quality Assurance
  • 8.1 Pediatric Oncology Shared Care Initial Data Transfer Sheet
  • 8.2 Shuttle Sheet
  • 8.3 Psychosocial Communication Tool
  • 9.1 Satellite Readiness/ Preparedness Checklist
  • 9.2 Education Report for Tertiary Centres
  • 9.3 Education Report for Satellite Centres
  • 9.4 Vital Signs Report
  • 9.5 Self- Assessment
  • 9.6 Satellite Contact Form
  • 9.7 Annual Satellite Caseload Report
  • 9.8 POGO Provincial Satellite Program Annual Accounting Report
Back to table of contents
Search our Manual
Have a question?
Contact us at: satellite@pogo.ca
  • About Us
    • Childhood Cancer Care Plan
    • Our Mission and Vision
    • Our Board
    • Our Partners
    • Our Donors
    • Privacy
    • History & Milestones
    • Reports
    • Newsroom
    • Job Opportunities
    • Accessibility
    • Staff List
  • Programs & Support
    • Patient Care Programs
    • Financial Assistance
    • Survivor Care
    • Cancer Resources
    • Childhood Cancer Resource Guide
    • Inspiring Stories
    • Clinical and Program Advisory Committees
  • Education
    • POGO AfterCare Education Day
    • POGO Multi-Disciplinary Symposium on Childhood Cancer
    • All Education Events & Conferences
  • Healthcare Practice
    • COVID-19 Updates
    • Pediatric Oncology Nursing
    • Clinical Practice Guidelines
    • Satellite Manual
  • Research & Data
    • 2020 POGO Surveillance Report
    • POGO Research Unit
    • POGONIS – Childhood Cancer Database
    • Data Reports
    • Data Requests
  • Get Involved
    • Pajamas and Pancakes
    • Birthday Parties for POGO
    • Events
    • Volunteer
  • Ways to Give
    • Donate
    • Gifts of Stock and Securities
    • Become a Corporate Partner
    • Gifts in Honour/Memory
    • Legacy Gifts
    • Shop Online/Earn Cash Back

©2020 Pediatric Oncology Group of Ontario

480 University Avenue, Suite 1014 | Toronto, Ontario, M5G 1V2, Canada | Charitable Registration Number: 871067245RR0001 | Contact Us
1-855-FOR POGO (367-7646) | Website Privacy Policy | Website Disclaimer | Satellite Manual Disclaimer |